<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05793463</url>
  </required_header>
  <id_info>
    <org_study_id>RC 03/17</org_study_id>
    <nct_id>NCT05793463</nct_id>
  </id_info>
  <brief_title>Anti-mullerian Hormone in Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Anti-mullerian Hormone in Pediatric Patients Treated for Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Burlo Garofolo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Burlo Garofolo</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with current&#xD;
      survival rates exceeding 90%. As cure rates improve, increasing attention is focused on&#xD;
      survivor quality of life, including fertility. It is generally accepted that cancer&#xD;
      treatments in childhood may interfere with gonadal function, reducing the pool of primordial&#xD;
      follicles and consequently causing premature menopause in women. Anti-Mullerian hormone (AMH)&#xD;
      levels is a valuable quantitative indicator of ovarian reserve, being directly related to the&#xD;
      number of antral follicles. The evaluation of this hormone makes it possible to identify&#xD;
      women at risk of early menopause and to propose them interventions for monitoring and&#xD;
      preservation of oocytes, allowing girls to be able to have children once they reach&#xD;
      adulthood. The objective of this study is to determine ovarian reserve in girls with ALL&#xD;
      before and after treatment by means of the evaluation of the AMH assay.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Anticipated">March 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of blood AMH levels before ALL treatment</measure>
    <time_frame>Within one months from ALL diagnosis</time_frame>
    <description>AMH levels will be evaluated in peripheral blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of blood AMH levels after ALL treatment</measure>
    <time_frame>24 months after ALL diagnosis</time_frame>
    <description>AMH levels will be evaluated in peripheral blood</description>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Female less than 18 years of age with ALL&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female less than 18 years of age&#xD;
&#xD;
          -  Diagnosis of acute lymphoblastic leukemia&#xD;
&#xD;
          -  enrollment within the first month after diagnosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatments with cytostatics drugs&#xD;
&#xD;
          -  ALL as a second malignancy&#xD;
&#xD;
          -  Syndromic patient or primary hypogonadism&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagua Giurici, MD</last_name>
    <role>Study Director</role>
    <affiliation>IRCCS materno infantile Burlo Garofolo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nagua Giurici, MD</last_name>
    <phone>+390403785342</phone>
    <email>nagua.giurici@burlo.trieste.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Burlo Garofolo</name>
      <address>
        <city>Trieste</city>
        <zip>34137</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nagua Giurici, MD</last_name>
      <phone>+390403785342</phone>
      <email>nagua.giurici@burlo.trieste.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Fertility preservation</keyword>
  <keyword>Anti-Mullerian hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

